Group 1 - The company, 英矽智能 (03696.HK), plans to globally offer 94.6905 million shares, with 9.4695 million shares available in Hong Kong and 85.221 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The offering price is set at HKD 24.05 per share, with a trading unit of 500 shares, and the shares are expected to start trading on December 30, 2025 [1] - The company was established in 2014 and operates as an AI-driven drug discovery and development firm, having generated over 20 clinical or IND-stage assets through its Pharma.AI platform [2][3] Group 2 - The company has a unique dual-engine business model that combines a generative AI platform with strong in-house drug development capabilities, significantly reducing the time from target discovery to clinical candidate confirmation to 12-18 months, compared to the traditional average of 4.5 years [3] - The company has entered cornerstone investment agreements totaling USD 115 million (approximately HKD 895 million), with cornerstone investors including Lilly, Tencent, and Temasek, among others [3] - The estimated net proceeds from the global offering, assuming no exercise of the over-allotment option, will be approximately HKD 2.0258 billion, with planned allocations for clinical R&D, AI model development, laboratory automation, early drug discovery, and general corporate purposes [4]
英矽智能(03696.HK)预计12月30日上市 腾讯及淡马锡等豪华基石阵容加持
Ge Long Hui·2025-12-17 23:39